NCT06766019View on ClinicalTrials.gov

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

"1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles"

Trial Locations (1)

025

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06766019 - Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter